← All trials
NCT04742036
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2021
- Primary completion
- Jul 29, 2022
- Completion date
- Jul 29, 2022
- First posted
- Feb 5, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.